A new paradigm for tumor immune escape: β-catenin-driven immune exclusion by unknown
COMMENTARY Open Access
A new paradigm for tumor immune escape:
β-catenin-driven immune exclusion
Stefani Spranger2* and Thomas F. Gajewski1*
Abstract
Increasing evidence is emerging that immunotherapeutic interventions, including checkpoint blockade, are
predominantly effective in patients with a pre-existing T cell-inflamed tumor microenvironment. Understanding the
mechanisms leading to a non-T cell-inflamed microenvironment are crucial for the development of novel treatment
modalities to expand the fraction of patients benefiting from immunotherapy. Based on the hypothesis that one
source of inter-patient heterogeneity would lie at differential activation of specific oncogene pathways within the
tumor cells themselves, our group recently observed that tumor-cell intrinsic activation of the WNT/β-catenin
pathway correlates with absence of T cells from the microenvironment in metastatic melanoma. Genetically-engineered
mouse models confirmed a causal relationship, via a mechanism of failed Batf3-lineage dendritic cell recruitment.
Hence, tumor cell-intrinsic activation of β-catenin is the first oncogenic pathway demonstrated to exclude the
anti-tumor immune response, revealing a potential therapeutic target for improving immunotherapy responsiveness.
Keywords: Tumor microenvironment, Immune evasion, Checkpoint inhibition, T-cell infiltration
Background
Despite the growing success of immunotherapy in the treat-
ment of advanced cancer, it is clear that only a subset of
cancer patients experience clinical benefit from these inter-
ventions. Recent biomarker observations have supported
the premise that most clinical responders to anti-PD-1
mAb, anti-CTLA-4 mAb, and cancer vaccines show a pre-
existing T cell-inflamed tumor microenvironment at base-
line [1–3]. Post-treatment biopsies from melanoma patients
receiving anti-PD-1 have revealed an expanded number of
proliferating CD8+ T cells penetrating deep within the
tumor microenvironment [4]. These data are consistent
with preclinical data demonstrating that most of the thera-
peutic effect of checkpoint blockade can be attributed to re-
activation of CD8+ T cells already present within the tumor
[5]. Patients with tumors that completely lack adaptive im-
mune cell infiltration may require novel therapeutic inter-
ventions to restore T cell entry and enable responsiveness to
our current immunotherapies. As such, understanding the
underlying mechanisms of T cell exclusion has become a
critically important biologic question with clinical relevance.
Main text
Our laboratory has been pursuing three potential levels
of inter-patient heterogeneity that could explain the
presence or absence of the T cell-inflamed tumor micro-
environment phenotype in individual patients: somatic
differences at the level of the tumor cells, germline poly-
morphism differences at the level of the host, and envir-
onmental differences at the level of the intestinal
microbiota. Beginning with the hypothesis that activa-
tion of specific oncogene pathways might mediate im-
mune exclusion in tumors from individual patients [6],
we utilized metastatic melanoma data from 266 tumor
samples from The Cancer Genome Atlas (TCGA) and
segregated them based on the presence or absence of a
gene signature indicative of the T cell-inflamed pheno-
type. Using these same tumors, exome sequencing and
pathway analysis were performed, which revealed that
48 % of the non-T cell-inflamed tumors showed evidence
for activation of the Wnt/β-catenin pathway. In order to
determine whether activation of the β-catenin path-
way was causally related to immune exclusion, auto-
chthonous mouse models were developed utilizing a
melanocyte-specific, tamoxifen-regulated Cre [7], paired
with conditional BrafV600E induction, PTEN deletion,
and/or β-catenin stabilization [8, 9]. While a T cell
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infiltrate was indeed observed in tumors driven by
BrafV600E and PTEN deletion, this T cell infiltrate was
completely absent in tumors that additionally expressed
active β-catenin. To further investigate the mechanism
of T cell exclusion, an SIY antigen-reporter mouse
(Rosa26-Lox-Stop-Lox-SIY) [10] was used in combin-
ation with adoptive transfer of SIY-specific TCR-
transgenic T cells (2C T cells). Although brisk activation
and tumor accumulation of the transferred T cells was
observed in in BrafV600E/PTEN mice, no such activation
or accumulation was observed in mice bearing tumors
additionally expressing active β-catenin. This observa-
tion prompted analysis of the antigen-presenting cell
compartment in both tumor types, which revealed a sig-
nificant reduction of CD103/CD8α dendritic cells (DCs)
in β-catenin-expressing tumors. Rescue experiments
utilizing intratumoral injection of Flt3 ligand-derived
DCs showed restoration of T cell infiltration. To probe
more deeply into the mechanism of failed recruitment of
Batf3-lineage DCs, gene expression profiling of the two
tumor genotypes was performed with a focus on chemo-
kines. These studies revealed BrafV600E/PTEN tumor
cells were capable of secreting the chemokine CCL4,
whereas no CCL4 expression was observed with tumor
cells that additionally expressed stabilized β-catenin.
These findings were confirmed using tumor cell lines
derived from both mouse models as well as with human
melanoma cell lines that contained or lacked active β-
catenin signaling. The ability of active β-catenin to pre-
vent CCL4 gene expression was mapped to induction of
a transcriptional repressor ATF3, which ChIP assays
confirmed was binding the CCL4 promoter. To explore
in vivo efficacy of checkpoint blockade with these two
tumor genotypes, mice were treated with a combination
of anti-CTLA4 and anti-PD-L1 mAbs. Although this
treatment delayed tumor outgrowth in BrafV600E/PTEN
mice, no therapeutic effect was observed in mice bearing
tumors that additionally expressed active β-catenin.
Responsiveness to checkpoint blockade was restored
through direct injection of FLt3L-derived DCs, demon-
strating the rate-limiting role of proper DCs for activat-
ing tumor antigen-specific T cells, which in turn allowed
for response to checkpoint inhibition.
Conclusion
The observation that oncogenic pathways within tumor
cells have the capability to directly impact the anti-tumor
immune response is likely to have impact on both the re-
search directions in the field and also on prioritization of
clinical development of new targeted inhibitors. Evasion
from the immune system is a well-known phenomenon,
but thus far it has been focused on immune-mediated se-
lection for antigen-loss variants, combined with upregula-
tion of immune inhibitory mechanisms that thwart the
efforts of remaining T cells having intermediate affinity
TCRs for remaining antigens. However, these mechanisms
failed to explain the existence of the non-T cell-inflamed
tumor microenvironment phenotype, which contain
tumor cells that express antigens but nonetheless fail to
support a dialogue with the host immune response. The
non-T cell-inflamed phenotype, in fact, is the most com-
mon pattern observed in human samples and in TCGA
data analysis across a spectrum of tumor types, and so un-
derstanding the biology of this mechanism of immune re-
sistance is paramount. It is likely that activation of the
Wnt/β-catenin pathway is relevant for immune evasion in
additional cancers beyond melanoma. Preliminary data
have indicated that the β-catenin pathway is associated
with T cell exclusion in bladder cancer and also in head
and neck cancer [11]. Inasmuch as β-catenin activation
accounted for 48 % of non-T cell-inflamed melanomas,
other oncogene pathways likely contribute to immune ex-
clusion in the remainder of these tumors, and similarly in
other cancers as well. Activation of the Ras/Raf pathway
has already been investigated to some degree in human
patients and early studies have suggested an increased in-
filtration by T cells after administration of Braf inhibitors
[12]. However, it is not yet clear if these T cells are tumor-
specific or whether their recruitment leads to productive
T cell activation versus dysfunction. The PI3K/PTEN
pathway is also being investigated, but with somewhat
contradictory data thus far. Analysis of samples from triple
negative breast cancer patients has indicated that loss of
PTEN is associated with presence of T cells within the
microenvironment. In contrast, data presented on malig-
nant melanoma has indicated the opposite [13, 14]. There-
fore, cancer-type specific mechanistic studies might be
needed to answer this question definitively. Continued in-
terrogation of these and other oncogene pathways in the
full range of tumor types should be stablished as a high re-
search priority. As each candidate oncogene-driven mech-
anism of immune exclusion is validated mechanistically,
then pharmacologic approaches to block these pathways
should be integrated into combination studies in concert
with immunotherapeutics such as anti-PD-1. It is tempt-
ing to speculate that a bidirectional iterative translational
research program identifying molecular mechanisms of
resistance immunotherapies and combination therapies
will ultimately lead to an expansion of clinical impact to
encompass the majority of cancer patients.
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